Skip to content
USA: +1 (952) 449 5206 & India:+91 7995114352info@iddresearch.com
Search
FacebookTwitterLinkedin
Innovative Drug Development
Innovative Drug Development
Science by Technology

Innovative Drug Development – Science By Technology

  • Home
  • Company ↓
    • Who We Are?
    • Vision & Mission
    • Our Team
    • Transition from i5 to iDD
  • Search for an Expert
  • Jobs
  • Contact Us
Top Menu
  • Products
    • iSmart
    • iPet
  • Clinical Drug Development
  • Clinical Research Organisation
  • Risk Based Monitoring
  • SCRO
  • SDMO
  • News & Events
  • Downloads
  • Products
    • iSmart
    • iPet
  • Clinical Drug Development
  • Clinical Research Organisation
  • Risk Based Monitoring
  • SCRO
  • SDMO
  • News & Events
  • Downloads

Author Archives: iddadmin

You are here:
  1. Home
  2. Article author iddadmin
  3. (Page 2)

From Durham, The Future Of Clinical Research Looks A Lot Like Implementation Science

Clinical Research, Clinical Research Industry, NewsBy iddadminAugust 9, 2018

MEI Pharma, Inc a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer.

Virtual clinical trials: Story of the ‘site-less’ model!

Clinical Research, Clinical Research Industry, NewsBy iddadminAugust 8, 2018

MEI Pharma, Inc a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer.

MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 ASCO Annual Meeting

Clinical Research, Clinical Research IndustryBy iddadminAugust 8, 2018

MEI Pharma, Inc a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer.

AbbVie Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse Large B-Cell Lymphoma and Ongoing Ibrutinib Clinical Program

Clinical Research, Clinical Research IndustryBy iddadminAugust 8, 2018

AbbVie , a research-based global biopharmaceutical company, announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA®) in untreated diffuse large B-cell lymphoma , an aggressive form of non-Hodgkin lymphoma.

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis

Clinical Research, Clinical Research IndustryBy iddadminAugust 8, 2018

Servier, an independent international pharmaceutical company, and the company Galapagos NV announce the start of a global

12345
© 2018 iDD Research Solutions INC | Website Concept by: GETONTHEWEB.IN
  • Cookie Policy
  • Privacy Policy
  • Site Map
  • Downloads
Bottom Menu